Jean-Charles Soria, Amgen’s senior vice president of Oncology within Global Development, shared an article on LinkedIn:
“Carcinoma of Unknown Primary: Cancer without a past.
- Early dissemination.
- Immune editing of the primary.
- CK20+, CDX2+, SATB2+ → treat colon-like.
Let biology, not anatomy, guide therapy.
Not a diagnostic failure — a metastatic strategy.”
Cancer of Unknown Primary Site.
Authors: Kanwal Raghav.
You can read the full article on The New England Journal of Medicine.
More posts featuring Jean-Charles Soria.